Deintensification of basal-bolus insulin after initiation of GLP-1RA in patients with type 2 diabetes under routine care.

Aims: We evaluated de-intensification of basal-bolus insulin (BBI) after initiation of a GLP-1 receptor agonist (GLP-1RA) under routine care.
Research Design and Methods: This retrospective, multicenter study conducted at outpatient clinics in North-East Italy collected data on patients with T2D on BBI who initiated a GLP-1RA. Patients were divided according to whether they de-intensified BBI at the end of observation by stopping prandial insulin.
Results: We included 425 patients with mean age of 61.3 years and 13 years of diabetes duration. Baseline HbA1c was 8.6% and BMI was 35.5 kg/m ² . After 14 months. 58.6% of patients de-intensified BBI after initiating GLP-1RA: they were younger, had a shorter disease duration, lower HbA1c and insulin dose, and less frequent microangiopathy than those who continued BBI. A probability estimation based on these variables was validated in an independent cohort of 40 patients. Body weight improved in both groups, but HbA1c and fasting plasma glucose significantly declined only among patients who de-intensified BBI. Patients who de-intensified BBI and persisted on GLP-1RA at the last observation (80.7%) had greater HbA1c reductions.
Conclusion: Under routine care, GLP-1RA initiation frequently allowed discontinuing BBI, especially among patients with shorter disease duration, lower insulin requirement, and better glucose control.
Competing Interests: Declaration of Competing Interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: B.M.B. received lecture or advisory board fees from Astra Zeneca, Eli Lilly, Boehringer Ingelheim, Novo Nordisk and Novartis. M.R. received lecture and advisory board fees from AstraZeneca, Boehringer Ingelheim, Eli Lilly, Mundipharma, Novo Nordisk. V.F. served as consultant for NovoNordisk. N.S. received lecture or consultancy fees from Astra-Zeneca, Boehringer-Lilly, Novartis, NovoNordisk, Sanofi-Aventis, Takeda, Merck Sharp & Dohme, and Abbott and research support from NovoNordisk. A.L. received grant support, lecture or advisory board fees from Novo Nordisk, Sanofi, Abbott, and Eli Lilly. A.A. received research grants, lecture fees, or advisory board fees from Merck Sharp & Dome, AstraZeneca, Novartis, Boehringer Ingelheim, Sanofi, Mediolanum, Janssen, Novo Nordisk, Eli Lilly, Servier, and Takeda. G.P.F. received grant support, lecture fees, or advisory board fees from Abbott, AstraZeneca, Boehringer Ingelheim, Eli Lilly, Novartis, Novo Nordisk, Sanofi, Genzyme, Servier, and Merck Sharp & Dohme. The remaining authors have nothing to disclose.
(Copyright © 2021 Elsevier B.V. All rights reserved.)